Study Complete
Sponsor ID
20101121
European physician survey of EGFR inhibitor prescribing patterns
Study Details
To ensure the appropriate administration of Vectibix for the treatment of mCRC with wild-type KRAS in real-world practice, it is important to understand the awareness of practicing oncologists regarding the correct indication and appropriate administration of Vectibix. It is also critical to monitor changes in oncologists’ awareness and practice between the different rounds of the study.
Protocol Summary
Primary Outcome Measures
Proportion of oncologists who are aware of the correct indication of Vectibix, with regard to tumor KRAS status and who conduct a KRAS test prior to initiation of Vectibix treatment
Timeframe: Trend survey of physicians performed over 3 years
Proportion of oncologists who conduct a KRAS test prior to the initiation of Vectibix treatment
Timeframe: Trend survey of physicians performed over 3 years
Proportion of oncologists who administer Vectibix in mCRC patients with mutant KRAS tumors or with KRAS status unknown
Timeframe: Trend survey of physicians performed over 3 years
Proportion of oncologists who administer Vectibix simultaneously with oxaliplatin-containing chemotherapy in mCRC patients with mutant KRAS tumors or patients with tumor KRAS status unknown
Timeframe: Trend survey of physicians performed over 3 years
Secondary Outcome Measures
Not Available
Locations
No locations found.